Text Size: A A A      Contrast:        Transparency in Coverage Rule

Genentech ELEVATUM - Diabetic Macular Edema (DME) in African American, Hispanic, or Native Americans

A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema (ELEVATUM)

Condition or Disease

Intervention / Treatment




Diabetic Macular Edema


Phase 4



Study Description:

This Phase 4 study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab (VABYSMO™).  The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander. 

Participants will receive 6-milligram (mg) intravitreal (IVT) faricimab injections once every 4 weeks (Q4W) up to Week 20, followed by 6-mg IVT faricimab injections once every 8 weeks (Q8W) up to Week 52. Participants will return for the Week 56 safety follow-up visit after ≥ 28 days following their last study treatment.

Inclusion Criteria:

General Inclusion Criteria:
  • Self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander.
  • Diagnosis of diabetes mellitus (type 1 or type 2), as defined by the World Health Organization (WHO) and/or American Diabetes Association, and current regular use of insulin or other injectable drugs (e.g., dulaglutide and liraglutide) and/or oral anti-hyperglycemic agents for the treatment of diabetes.
  • Hemoglobin A1c (HbA1c) ≤10% (Note: up to 20% of participants enrolled may have HbA1c up to 12%).
  • For women of childbearing potential: Agreement to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraception methods as defined in the protocol.
Ocular Inclusion Criteria for Study Eye:
  • Intravitreal (IVT) treatment-naïve in the study eye (i.e., have not received previous treatment with any anti-VEGF IVT or any corticosteroids periocular or IVT in the study eye).
  • Diabetic macular edema, defined as macular thickening by SD-OCT involving the center of the macula.
  • BCVA letter score of 73 to 20 letters (both inclusive) using the ETDRS protocol at the initial testing distance of 4 meters at the baseline visit (Day 1).
  • Clear ocular media and adequate pupillary dilation to allow acquisition of good quality retinal images to confirm diagnosis.
Exclusion Criteria:

Ocular Exclusion Criteria for Study Eye:
  • High-risk proliferative diabetic retinopathy (PDR) in the study eye, using any of the following established criteria for high-risk PDR: Any vitreous or pre-retinal hemorrhage; Neovascularization elsewhere ≥1/2 disc area within an area equivalent to the mydriatic ETDRS 7 fields on clinical examination or on CFPs; Neovascularization at disc ≥1/3 disc area on clinical examination.
  • Tractional retinal detachment, pre-retinal fibrosis, vitreomacular traction, or epiretinal membrane involving the fovea or disrupting the macular architecture in the study eye, as evaluated by the central reading center.
  • Any history of or ongoing rubeosis iridis.
  • Any panretinal photocoagulation or macular laser (focal, grid or micropulse) photocoagulation treatment received in the study eye prior Day 1.
  • Any history of treatment with anti-VEGF or any periocular or IVT corticosteroids in the study eye prior to Day 1.
  • Any treatment for dry eye disease in the last month prior to Day 1 (e.g., cyclosporine eye drops, lifitegrast eye drops). Lubricating eye drops and ointments are permitted.
  • Any treatment with anti-inflammatory eye drops (e.g., doxycycline) within 1 month prior to Day 1.
  • Any intraocular surgery (e.g., cataract surgery) within 3 months prior to Day 1 or any planned surgery during the study.
  • Any glaucoma surgery prior to the screening visit.
  • History of vitreoretinal surgery/pars plana vitrectomy, corneal transplant, or radiotherapy.
  • Uncontrolled glaucoma.
  • Any active or suspected ocular or periocular infections on Day 1.
  • Any presence of active intraocular inflammation on Day 1 (i.e., Standardization of Uveitis Nomenclature [SUN] criteria > 0 or National Eye Institute [NEI] vitreous haze grading > 0) or any history of intraocular inflammation.
  • Any history of idiopathic, infectious, or noninfectious uveitis.
  • Any current ocular condition or other causes of visual impairment for which, in the opinion of the investigator, visual acuity loss would not improve from resolution of macular edema.
Ocular Exclusion Criteria for Non-Study Eye:
  • Any history of idiopathic or immune-mediated uveitis.
  • Active ocular inflammation or suspected or active ocular or periocular infection on Day 1.
  • Currently receiving treatment with brolucizumab or bevacizumab in the non-study eye and is unwilling to switch to a protocol-allowed, non-study eye anti-VEGF treatment during the study.
  • Any previous treatment with Iluvien® or Retisert® (fluocinolone acetonide IVT implant) in the non-study eye.
  • Non-functioning non-study eye, defined as either: BCVA of hand motion or worse; No physical presence of non-study eye (i.e., monocular); or, Legally blind in the patient's relevant jurisdiction.
General Exclusion Criteria:
  • Diabetes mellitus (type 1 or type 2) that is currently medically untreated.
  • Previously untreated diabetes mellitus (type 1 or type 2) who started on oral or injectable anti-diabetic medication within 3 months prior to Day 1.
  • Any known hypersensitivity to any of the components in the faricimab injection.
  • Any known hypersensitivity to any contrast media (e.g., fluorescein), dilating eye drops, disinfectants (e.g., iodine), or any of the anesthetics and antimicrobial preparations used by the patient during the study.
  • History of other diseases, other non-diabetic metabolic dysfunction, physical examination finding, or historical or current clinical laboratory finding giving reasonable suspicion of a condition that contraindicates the use of the faricimab or that might affect interpretation of the results of the study or renders the patient at high-risk for treatment complications, in the opinion of the investigator.
  • Active cancer within the past 12 months prior to Day 1 except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer with a Gleason score of ≤ 6 and a stable prostate-specific antigen for > 12 months.
  • Stroke (cerebral vascular accident) or myocardial infarction within 12 months prior to Day 1.
  • Any febrile illness within 1 week prior to Day 1.
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of faricimab.
  • Uncontrolled blood pressure, defined as systolic > 180 mmHg and/or diastolic > 100 mmHg (while patient is at rest in a sitting position); if a patient's initial reading exceeds these values, a second reading may be taken ≥ 30 minutes later on the same day.
  • Renal failure requiring renal transplant, hemodialysis, or peritoneal dialysis within 6 months prior to Day 1 or anticipated to require hemodialysis or peritoneal dialysis at any time during the study.
  • Any condition resulting in a compromised immune system that is likely to impact the aqueous humor inflammatory biomarkers.
  • Participation in an investigational trial that involves treatment with any drug or device (with the exception of vitamins or minerals) within 3 months (or 5 half-lives, whichever is longer) prior to Day 1, or during the course of this study.
  • Substance abuse occurring within 12 months prior to screening, in the investigator's judgment.
  • Use of systemic immunomodulatory treatments (e.g., IL-6 inhibitors) within 6 months or 5 half-lives (whichever is longer) prior to Day 1.
  • Use of any systemic corticosteroids within 1 month prior to Day 1.
  • Systemic treatment for suspected or active systemic infection.
  • Any prior or concomitant systemic anti-VEGF treatment within 6 months or 5 half-lives (whichever is longer) prior to Day 1.
  • Use of systemic medications known to be toxic to the lens, retina, or optic nerve (e.g., deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, phenothiazines, or ethambutol) during the 6 months (or 5 half-lives, whichever is longer) prior to Day 1.
  • Receiving any treatment that leads to immunosuppression within 6 months (or 5 half-lives, whichever is longer) prior to Day 1.
  • Requiring continuous use of any medications or treatments listed as prohibited therapy. 

Beachwood Office:  Richard Donkor   216-831-5700    •   rdonkor@retina-assoc.com.  
Middleburg Heights Office:  Maureen Cunningham  440-663-0022   •   mcunningham@retina-assoc.com.

To learn more: